Kallenberg C G, Pastoor G W, Wouda A A, The T H
Ann Rheum Dis. 1982 Aug;41(4):382-7. doi: 10.1136/ard.41.4.382.
Antinuclear antibodies (ANA) were detected in the sera of 73 out of 138 patients (53%) referred to us because of Raynaud's phenomenon. When ANA were found, systemic manifestations were likely to be present. The use of human fibroblast monolayers as a nuclear substrate allowed differentiation of several fluorescence patterns, including the discrete speckled variety produced by anticentromere antibodies. These antibodies were detected in the sera of 7 out of 10 patients with CRST syndrome (70%), in 7 out of 40 patients with scleroderma (18%), all without kidney-involvement, in one patient with Sjögren's syndrome and severe Raynaud's phenomenon, and in 7 patients with Raynaud's phenomenon associated with a few symptoms of a connective tissue disease (especially scleroderma). ANA testing on tissue culture monolayers in Raynaud's phenomenon appears to be of value in predicting systemic disease manifestations and the presence or possible future development of distinct clinical patterns, especially the CRST syndrome.
在因雷诺现象转诊至我院的138例患者中，73例（53%）血清检测出抗核抗体（ANA）。发现ANA时，可能存在全身表现。用人成纤维细胞单层作为核底物可区分几种荧光模式，包括由抗着丝点抗体产生的离散斑点型。在10例CRST综合征患者中的7例（70%）、40例硬皮病患者中的7例（18%）（均无肾脏受累）、1例干燥综合征合并严重雷诺现象的患者以及7例伴有一些结缔组织病症状（尤其是硬皮病）的雷诺现象患者的血清中检测到了这些抗体。对雷诺现象患者进行组织培养单层ANA检测，对于预测全身疾病表现以及特定临床模式（尤其是CRST综合征）的存在或未来可能发展似乎具有价值。
